Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784883 | 0.91 | F10 (0.37) | F10NPY5RALDH1A1ALOX15 | |
| SCHEMBL785512 | 0.85 | F10 (0.40) | F10CNR2NPY5RROCK2 | |
| SCHEMBL484563 | 0.83 | CYP3A4 (0.47) | ALDH1A1 | |
| SCHEMBL784827 | 0.83 | ROCK2 (0.37) | F10NPY5RALDH1A1ALOX15ROCK2 | |
| SCHEMBL785132 | 0.82 | F10 (0.38) | F10NPY5RALDH1A1ALOX15ROCK2 | |
| SCHEMBL785712 | 0.81 | F10 (0.37) | F10NPY5RALDH1A1ALOX15ROCK2 | |
| SCHEMBL784500 | 0.81 | ALDH1A1 (0.39) | F10NPY5RALDH1A1ALOX15ROCK2 | |
| SCHEMBL785090 | 0.81 | BDKRB1 (0.40) | F10ALDH1A1ALOX15CCR5 | |
| SCHEMBL783957 | 0.81 | TRPV1 (0.40) | F10ALDH1A1ALOX15CCR5JAK2 | |
| SCHEMBL785527 | 0.80 | TRPV1 (0.38) | F10ALDH1A1ALOX15JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | F10 524/4885CNR2 38/4885NPY5R 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.